Embed Size (px)
Citation preview
1
Free
First 50 attendants
Wed., January 27, 2021 13:00-14:00 JST Startup Pitches; 12:40-15:00 Virtual Demo/Exhibits
HostHal MorimotoAstoria (US)
Toru SeoPfizer Inc.
SleepWell VORONOI MiiBio Spacevision Detalytics Kang Healthcare
睡眠化学を手のひらに
Startups Showcased at the FORUM
Startups introduced in Januaryv ERISA (Image analyses using AI) v Biolite Japan (Medical Device for Vitreous substitute for retina)v ThinkCyte (A technology platform using a novel AI-driven cell sorting technology) v SleepWell (Medical Device for Sleep disorders) v Veronoi Bio (Drug discovery program) v MiiBio (Technology platform for Gene editing) v Spacevision (3D scanning instrument for life sciences etc.) v Detalytics (Purpose-driven analytics for health, risk and performance management)v Kang Healthcare (Medical Device for breast cancer detection and infertility) (TBC)
Program12:45 ‒ 13:00 Introduction/ Virtual Lounge Orientation @ZOOM MeetingWelcome Note/Outline of the Event, Virtual Lounge Orientation
13:00 ‒ 14:00 Panel Interview + Virtual Pitches (Live) @ZOOM MeetingIntroducing Presenters, Pitch Presentations by Startups, About Presenters in February (in English)
13:00 ‒ 15:00 Virtual Exhibit Booth + Theater + Private Meeting @Virtual LoungeLive presentations/Pre-recorded Pitches by Startups @Virtual Demo Table/Virtual Exhibit BoothOne-on-one meeting with Startup Presenters @Virtual Lounge (Private Room)
BornGlobal FORUM ‒ Pitch Event 1on Japan & Asia
ERISA BioLite Japan ThinkCyte
Host Collaborators
BornGlobal FORUM 主催Astoria Consulting Group, LLCemail: [email protected]
LINK-J Pfizer J-Startup BioLite Japan
It is as if you are meeting in-person
Identify a potential match from short pitch presentations
Gather more detailed information at
Virtual Demo Table
Meet one-on-one with the startups of your choosing
2
アジェンダ12:45 ‒ 13:00 JST バーチャルラウンジのオリエンテーション ◉ズーム上のセッションにて主催からのご挨拶・フォーラム＆ピッチイベント全体の流れについて・バーチャルラウンジオリエンテーション13:00 ‒ 14:00 JST パネルインタビュー・バーチャルピッチ（実演) ◉ズーム上のセッションにて参加者のご紹介＋スタートアップ企業による5分プレゼンテーション＋2月のイベントについてご紹介 (日・英語）13:00 ‒ 15:00 JST バーチャル展示ブース・ラウンジにて 商談 ◉バーチャルラウンジにて●個別のスタートアップ企業によるライブ・録画の詳細事業ピッチ ◉バーチャルDemo Table/展示ブースにて●スタートアップ企業との個別面談 ◉バーチャルラウンジ(個室エリア)にて
ボーングローバル・フォーラム１ピッチイベント 日本・アジア編
総合司会森本晴久アストリア
瀬尾 享氏ファイザー
スリープウェル VORONOI MiiBio Spacevision Detalytics Kang Healthcare
ピッチプレゼンに参加するスタートアップ
無料先着50名
睡眠化学を手のひらに
発表企業v ERISA (Image analyses using AI) v American BriVision Co./Biolite Japan (Medical Device for Vitreous substitute for retina v ThinkCyte (A technology platform using a novel AI-driven cell sorting technology) v SleepWell (Medical Device for Sleep disorders) v Veronoi Bio (Drug discovery program) v MiiBio (Technology platform for Gene editing) v Spacevision (3D scanning instrument for life sciences etc.) v Detalytics (Purpose-driven analytics for health, risk and performance management)v Kang Healthcare (Medical Device for breast cancer detection and infertility) (TBC)
日本にいながら世界のエコシステムと出会える、それがボーングローバル
画期的なバーチャル・ビジネスマッチングを是非体験してみてください
”ショートピッチ”の中から関係有りそうなスタートアップに目星をつけ
バーチャル展示ブースの”デモ・テーブル”で詳細説明を受け
コレは！と思う相手と”商談スペース”にてプライベートな対面打ち合せを持つ
ERISA BioLite Japan ThinkCyte
主催 協力機関
BornGlobal FORUM 主催Astoria Consulting Group, LLCemail: [email protected]
LINK-J Pfizer J-Startup BioLite Japan
Yoshiyuki NOTSUDirector, Chief Development Officer
ERISA Co., LTD.
✔13 years for a research reagent manufacture in business
development, PR/IR and so on
✔2 years for 2 start-ups in reproductive and regenerative medicine
Companion diagnostic "program" that predicts the
progression to Alzheimer's disease from MRI images
CONTACT: Yoshiyuki NOTSU, Director & CDO
E-mail: [email protected]
Mobile: +81-90-9987-9184
Supports diagnosis of Alzheimer's disease from brain atrophy, which is characteristic of Alzheimer's
disease, through image analysis using artificial intelligence
Main business
Drug discovery support
Dementia risk inspection
Diagnostic aid program sales ;CADx
Will verify the success of appropriate patient recruitment in past clinical trials. And we
will support the recruitment of patients in the future.
We will provide a new risk test for Alzheimer's disease in addition to the existing brain
dock test.
Obtained approval for software medical devices and sold to medical institutions for the
purpose of diagnostic support
CADx for Future risk of Alzheimer's disease
Accuracy 0.89
Sensitivity 0.89
Specificity 0.89
Odds ratio 65.5
ROC=0.94
Our model
Disease risk analysisIndividual predictions using
deep survival analysis
Age, gender and brain MR images are the only data required for analysis
Dementia
Major depression Schizophrenia
Shimane Univ.
Keio Univ.
Tokyo Metropolitan Geriatric
Hospital and Institute of
Gerontology
OPTiM Corporation
Medical Care Service
Company Inc.
Digital Garage, Inc.
Shiga Univ. of
Medical Science
Health Science Center
Shimane
Shimadzu Corporation
Developing a brain MR image diagnosis program
ビ ジ ョ ン
Vitargus®
• A biodegradable in situ-forming hydrogel, composed of oxidized hyaluronic acid (oxi-HA)
• For vitrectomy associated with procedures for retinal detachment/hemorrhage
2
First-in-Class Hydrogel Vitreous Substitute
Vitreous
Vitargus® has superior characteristics to currently available Products
Vitargus®Short-term
Vitreous Substitutes (Air/ Gas)
Long-term Vitreous Substitutes
(Silicone oil/ PerfluoronTM)
Maintaining face-down position
XVision 1-day Recovery 3-week Recovery Blurry
2nd Surgery to remove XCataract Surgery X X
3
• CAGR 6.8% globally, Asia Pacific (CAGR = 8.0%)
• The global retinal surgery device market is valued at over $3B by 2025
• Expected revenues ~ ~1B USD
• Augmented market cap via potential application for cataract surgery
4
Market Potentials
Rapid Growth in Vitreo-retinal Surgery Device Market
Vitargus®Works with you to create a
bright future!
Thanks!
11
For further discussion, please contact to
Or take a picture below
1
THINKCYTE, INC.
Deeper insights, better treatments - single cell at a time
Leveraging the world’s first and fastest image-based cell sorting technology,
we provide a platform that transforms
cell therapy, clinical diagnostics, and drug discovery
Hardware BiotechnologyInformation
Science
Restricted
Restricted 2
Leadership Team
Total 25 employees with
different fields of expertise
Ex-biotech startup, management consulting
(INSEAD MBA)
Waichiro Katsuda
Co-founder, CEO
Assc. Prof., Univ. of Tokyo(UC Berkeley PhD)
Sadao Ota, PhD
Co-founder, CSO
Ex-Senior Researcher, Otsuka Pharma
(Nagoya Univ. PhD)
Keiki Sugimoto, PhD
SVP, Research
Ex-Mech Engineer, Epson(Kyoto Univ. MS)
Keiji Nakagawa
Chief Product Officer
Ex-Manager, Mitsui & Co. (Univ. of Tokyo MS)
Hikaru Nagahori, CPA
Chief Business Officer
Ex-Assist. Prof., Tokyo Univ.Researcher, Duke Univ.
(Kyoto Univ. PhD)
Asako Tsubouchi, PhD
Head of Drug Discovery
Ex-Global Head of IP/Litigation, Takada Pharma
(Kyoto Univ. PhD)
Eiji Nara, PhD
VP, IP/Legal
Ex-Assist. Prof., Keio Univ.Researcher, Stanford Univ.
(Keio Univ. PhD)
Yoko Kawamura, PhD
Head of Microfluidics
Existing Methods of Cell Analysis and Isolation
Method for simultaneous output of
high content & high throughput is missing
1. Microscopes need manual manipulation and are
very slow
2. Cell sorting based on antibody-labeling (FACS,
MACS) can only provide the average information
Restricted 3
Challenge
?Micro-
scope
FACS
Speed
Info
rmatio
n
GHOST CYTOMETRY™ (GC)
Ultrafast imaging x Machine learning
GC enabled real-time high-content and
high-throughput analysis and sorting
1. Isolate target cells that are “unsortable” by current
methods
2. Classify cells based on high-content morphologic
information, even when it is visually unclear
Restricted 4
Our Solution
Micro-
scope
FACS
Speed
Info
rmatio
n
Restricted 5
Recognition from Leading Scientists
Remarks by leading scientists*
“This is the first instrument that allows the
physical sorting of cells based on their
morphology. This is revolutionary.”
―― Anne Carpenter, PI at the Broad
Institute of MIT and Harvard
“…Ghost cytometry could make this possible
by pinpointing features such as the size and
shape of the nucleus….If it takes off, it will
change the field of cell sorting and
cytometry permanently.”
―― Andrew Filby, Director of Flow Cytometry
Core Facility at Newcastle University
* Source: “Ghost Cytometry May Improve Cancer Detection,
Enable New Experiments”, Scientific American, June 14, 2018
Publication
in Science
2018
Market Opportunity
$13.3
$38.7
$0.0
$10.0
$20.0
$30.0
$40.0
2019F 2024F
Revenue (
$B
N)
$54.0
$62.0
$0.0
$10.0
$20.0
$30.0
$40.0
$50.0
$60.0
$70.0
2019F 2020FR
evenue (
$B
N)
$39BN $62BN
CELL
THERAPY
DRUG
DISCOVERY
CLINICAL
DIAGNOSTICS
End market size is expected to reach total $120BN by 2024, registering a CAGR of 24% in cell therapy market
$20.0
$22.0
$0.0
$5.0
$10.0
$15.0
$20.0
$25.0
2019F 2024F
Revenue (
$B
N)
$22BN
Restricted 6
1
連絡先（メールアドレス）
1
Sleep evaluation and depression diagnosis systemusing electroencephalograph of medical device
SleepWell.Inc
Decreased consciousness due to decreased brain activityDefinition of sleep
2
30 minutes to wear1night hospitalizationMachine learningin 2000 cases
Anywhere
• At home
Easy
• Easy to operate
Accurate
• AI accuracy
3
Socially implemented as a medical device.Japanese Government Authentication number ︓227ADBZX00087000
Japanese healthy person︓50,000 night
What we want to achieve: Application of sleep EEG to other diseases
What has been achieved: Clarification of sleep quality
4
Summary
1. Saving doctors and patients through medical use2. Verification of products that improve sleep quality
1. Understand the quality of sleep for various diseases(Use as a screening tool or submarker for clinical trials)2. New biomarkers for central nervous system diseases(e.g.depression)
1 This document is for discussion purpose only. Copyright ⓒ 2020 by VORONOI Inc. All rights reserved. No part of this document may be reproduced, stored in a retrieval system, used in a spreadsheet, or transmitted in any form or by any means ⎯
electronic, mechanical, photocopying, recording, or otherwise ⎯ without the permission.
1
Introduction to Voronoi
Precision Medicine-Focused Small molecule kinase inhibitors
Oncology, Neuroscience and Autoimmune Diseases
/ Intro
• Established in 2015
• Incheon, Korea
• Private-stage Company
• Dana-Farber Cancer
Institute as stakeholder
(1st in Korea)
2 Copyright ⓒ 2020 by VORONOI Inc. All rights reserved. No part of this document may be reproduced, stored in a retrieval system, used in a spreadsheet, or transmitted in any form or by any means ⎯ electronic, mechanical, photocopying, recording,
or otherwise ⎯ without the permission.
Rich dataset of biochemical assays and binding affinity on proprietary compounds from unique pharmacophores
Full Stack Library of Kinase Inhibitors / Platform
Virtual
Library
Experimental
Library*
Company A Company B
No Experimental
Data
Company C
Structurally
Similar Cmpds Limited Targets
* Binding affinity, catalytic inhibition and other biochemical assays
3 This document is for discussion purpose only. Copyright ⓒ 2021 by VORONOI Inc. All rights reserved. No part of this document may be reproduced, stored in a retrieval system, used in a spreadsheet, or transmitted in any form or by any means ⎯
electronic, mechanical, photocopying, recording, or otherwise ⎯ without the permission.
Oncology Pipeline Target Indication
EGFRexon20
CNS NSCLC
Discovery Preclinic Clinic Differentiation/TPP Stage
FIH ‘21 Brain penetration
RET NSCLC, MTC FIH ‘22 Addressing solvent front and
gatekeeper mt
STAT3 Solid tumor Protein Degrader Hit
MPS1
CNS GLP tox T.I. > x6 based on 14d rat DRF RB1 loss solid tumor
HER2
CNS
Breast Cancer
CRC, Gastric Cancer
Better brain penetration
NRG1-induced bypass
cKIT
Systemic
GIST / Systemic
Mastocytosis
Lead
Lead Brain impermeable sparing KDR
Hit HPK1 Solid tumor Comparable monotherapy
efficacy to competitors
IRAK4
CNS Lymphoma, Leukemia
NF-κB elevated, IRAK4-L form
heme Hit
Hit NUAK2 Solid tumor; meningioma,
TNBC and Liver cancer NF2 dysfunction solid tumors
Discovery SIK2
Systemic Ovarian Cancer; TNBC Sparing SIK3 x30-folds
/ Pipeline
4 This document is for discussion purpose only. Copyright ⓒ 2021 by VORONOI Inc. All rights reserved. No part of this document may be reproduced, stored in a retrieval system, used in a spreadsheet, or transmitted in any form or by any means ⎯
electronic, mechanical, photocopying, recording, or otherwise ⎯ without the permission.
Neuroscience & Immunology Pipeline Overview
Target Indication
DYRK1A
Systemic Atopic Dermatitis, IBD
Discovery Preclinic Clinic Differentiation/TPP Stage
IND
enabling Modulation of Tregs
DYRK1A
CNS Discovery Alzheimer’s Disease DYRK1A phosphorylates Tau
LIMK2
CNS Discovery
Autism, Alzheimer’s
Disease
Changes in LIMK signaling
associated w/neurodegenerative
diseases
RIPK1
CNS
Lead
Optimization
ALS, MS, Parkinson’s
Disease, Alzheimer’s
Disease
Equipotency across species
enables better translation
PDGFR
Systemic
Lead
Optimization
Idiopathic Pulmonary
Fibrosis; Systemic Sclerosis
Sparing FGFR and VEGFR;
Favorable DMPK profile
RIPK1
Systemic
Lead
Optimization
Inflammatory Bowel
Disease Superior efficacy to GSK’547
Hit SIK2
PO, Topical
Autoimmune Diseases
including Vitiligo Sparing SIK3 x30-folds
/ Pipeline
Established on April 1, 2019
MakingLife PhenomenaControllable!ON⇔OFF Switching Technology
Key Technologies Developed Lately
CRISPRCas9
iPS CellsOncolytic
Virus
Gene Therapy
RegenerativeTherapy
CancerTherapy
1Copyright © miibio, Inc. All Rights Reserved.
Introduction
Treatment SafetyDue to Uncontrollable
2
Issues
• Off Target• Gene Overexpression• Side Effects
Copyright © miibio, Inc. All Rights Reserved.
by providingON ⇔ OFF switch
3
Our Solution
Copyright © miibio, Inc. All Rights Reserved.
A
B
A B
Dark
Blue Light ONOFF
※ Nature Communications 2015
the photo-switch protein
4
Our Technologies
Copyright © miibio, Inc. All Rights Reserved.
ON⇔OFF Switch System
Targeted Gene
Activate
Targeted Gene
Magnet system
Split-dCas9 (Inactive)
MS2 p65HSF1
Guide RNAwith MS2-aptamers
Activator
mRNA
Protein
※ Nature Methods 2017
ON / AcceleratorOFF / Brakes
5Copyright © 2020 miibio, Inc. All Rights Reserved.
Our Technologies
ON⇔OFF Gene Expression
6
Photo-switching Gene Expression
Inner Body
Approach to Gene Therapy
AAVs
Gene Transfer with ON⇔OFF Switch
Monitoring and Controlling Gene Overexpression
LightON⇔OFF
Copyright © miibio, Inc. All Rights Reserved.
LightON⇔OFF
Information
CEO/Founder
Kensho Hayamizu
Serial Entrepreneur
Materials Science at
the Tohoku University
■Company
■Address
■Founder
miibio, Inc. ／ Established on April 1, 2019
Minato-ku, Tokyo, JAPAN
Kensho Hayamizu, Prof. Moritoshi Sato, etc
mail: [email protected]
Leading company in 3D imaging technology
3D BODY DATA SOLUTION
BornGlobal Forum 2021
CYBER world
3D SCANNING SERVICE ( STUDIO )（DEPARTMENT STORE, SHOPPING MALL, GYM, HOSPITAL）
VISIT & SCAN
NEW SERVICE
ONLINE SERVICE
REAL world
END USER
PortalApp
DATA REGISTRATION
API
ENGINE
DATA
DATAAPI
3D DATA ECO-SYSTEM : HUMANMETRICS
2
3D FACE SCANNER - SCUVE G4
3D BACK SCANNER ™Medical Device
in corporate with Keio Univ. &JOMDD
4FDVSJUZ
'BTIJPO��#FBVUZ
1FSTPOBM�%FTJHO
&OUFSUBJONFOU
"SU
)FBMUI���.FEJDBM
3D DATA ECO-SYSTEM
[ HUMANMETRICS ]
3D BODY SCANNER - SCUVE G4
OUR SERVICE &PRODUCTS
4
ADVANCED 3D TECHNOLOGIES ORIGINAL 3D SENSING AI & APPLICATION SOFTWARE STATISTICAL ANALYSIS PATENTED TECHONOLGY
ACADEMIC RESEARCHES KEIO & NIT UNIV.
BEHIND Our technology
5
PURPOSE-DRIVEN ANALYTICS FORHEALTH, RISKS & PERFORMANCE MANAGEMENT
PERSONALIZED BEHAVIORAL ANALYTICS ENGINE FOR WORK & LIFE
01 PROBLEMS WE SOLVE
MENTAL HEALTH is the echo pandemic following COVID-19
OUR SOLUTIONS ADDRESS EACH PROBLEMChronic diseases linked to
MODIFIABLE LIFESTYLE BEHAVIORS represent a global crisis
Work risks associated with SLEEP, FATIGUE and BURNOUT are global
Fast AGEING world population and workforce
UNSUSTAINABLE HEALTHCARE COSTSassociated with lifestyle diseases
NCDs COSTS MAGNITUDE
Detalytics Confidential
02 DETALYTICSSOLUTIONS
Your evidence-based profile in :• Physical health risk•Cognitive wellbeing• Personality
• Cardio-metabolic illnesses management
• Diabetes management• Obesity Management• Aging/Eldercare • Mental health management
• Lifestyle Behaviors• Metabolic Profile• Cognitive Health• Personality Profile
SmartphoneDEVICE NEEDED
AI / ML
DATA
ASSESSMENTS
USE CASES
Detalytics Mobile App
Wearables Medical IOT
Medical-grade Questionnaires
• Facial• Body, • Gait, Mobility
Raw data from wearables Data & Measurements
• Cardio-metabolic risks• Type II Diabetes risks• Cognitive state & mood• Mobility proficiency
• Food intake• Voice
Smartphone Camera
• Wellbeing optimization• Anti early-aging management• Travel health - including jet lag mgmt.
• Mental wellbeing management• Lifestyle illnesses management
• Readiness for task/shift (aviation, healthcare, logistics, transport, etc)
• Readiness for flight (pilots)
• Daily lifestyle impact• Recommendations to
correct lifestyle behaviors
• Fatigue status• Ready energy status• Cognitive perf.
Detalytics1 2 3
Your Personal Science-based Health & Wellbeing Assistant That Grows With Your Needs
Evidence-based Wellbeing TransformationYour journey with Detalytics
¤ Body & Mind
¤ Modular and scalable entry points
§ Smartphone§ Computer Vision Analytics§ Voice Analytics§ Wearables§ Medical grade IOT
¤ Curated contents to build resilience
¤ Team-based gamification for peer support
¤ “Pay-it-Forward” e-Wallet
• External contents providers• External solution providers• Telehealth providers
O p e n A P I E x c h a n g e
¤ Lifestyle ‘deficits” to improve
¤ Reference to gold standards in med. science
ASSESSMENT RECOMMENDATIONS INTERVENTION SUSTAINABLE RESILIENCE
05 THE TEAM
Dr. Florence H-Jennings PhD. MSc. MSoSc. MSc (Eng.)
Co-founder, Chief Scientist, R&D France - Singapore
Sha WangB(Eng.) Computer Science
Co-founder, CTOChina - Singapore
FOUNDERS
Michael HamouBoard Chairman
France
André BensimonBoard President
France
Dr. Tito Manrique PhDMathematics Biostatistics
France
Gark TanCOO
Singapore
TEAM
Machine Learning & Computer Vision
Anmol MohanComputer Vision and Facial Analytics
JP PatraMachine Learning
TEAM Data Science
Dr. Alex Kerss PhDData Scientist,
Mathematical models & algorithms
Dr. Mohammad Reza Keshtkaran, PhD Data Scientist, Machine Learning
Mengyu ShenJunior Data Scientist,
Statistician
Richard SchmoettenTheoretical and Mathematical Physics, Machine Learning
Sai Vara Lakshmi Bhandaram
Data Scientist,Product Growth Management
Dr. Sudhir N. Pathak, PhDComputational Physicist,Data Scientist
Nhat DangSoftware Developer
Alving NgSoftware Developer
Software Development
Felix HennigSoftware Developer
Abhishek PandeySoftware Developer
Shu Min LimGraphic Advisor
Dorothy MacabeoUI/UX Advisor
UI/UX Design
Juriani Johar YoUI/UX Advisor
Dr. Brian Wells MDSenior Consultant Psychiatrist
Addiction Expert
Dr. Jamie Phillips MDHuman Resilience- Elite Performance- Command and Leadership Advisor
Dr. Rafael Grossmann MDTrauma Surgeon.
Medical Technology and Surgical Applications Advisor
Dr. Sandor Bekasi MD. MscMedical Consultant, Mobile Health Applications Europe
Dr. Sundeep Chohan MDRemote and Hostile
Environments Medicine
Dr. Eudes Ménager de Frobervil MDEmergency Medicine, Vascular and
Stroke Expert, Sleep ConsultantSpecialist in eHealth, Innovation and
eDiabetes
Dr. Terence Tan MDOccupational
Medicine
Dr. Jacques Durand MDDigital Health and Aviation Medicine
MEDICAL CONSULTANTS & PARTNERS
